lenalidomide has been researched along with Obesity in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dong, H; Hu, N; Jiang, S; Jones, KR; Kang, YM; Luo, F; Ren, J; Xiong, L; Zhu, X; Zou, Y | 1 |
Dong, M; Hua, Y; Jones, KR; Li, L; Li, Q; Ren, J; Smith, DT; Yuan, M | 1 |
2 other study(ies) available for lenalidomide and Obesity
Article | Year |
---|---|
Tumour necrosis factor-α inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice.
Topics: Animals; Apoptosis; Blood Glucose; Gene Expression Regulation; Glucose; Immunologic Factors; Intestine, Small; Kidney; Lenalidomide; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Oxidative Stress; Thalidomide; Tumor Necrosis Factor-alpha | 2014 |
Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice.
Topics: Absorptiometry, Photon; Animals; Blotting, Western; Caspases, Effector; Cells, Cultured; Endoplasmic Reticulum; Fas Ligand Protein; Interleukin-6; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Myocardial Contraction; Myocytes, Cardiac; Obesity; Signal Transduction; Thalidomide; Tumor Necrosis Factor-alpha | 2012 |